Organ-specific inflammation masquerades as relapse in CAR T-cell remission

Researchers at Friedrich-Alexander-Universität Erlangen-Nürnberg have identified a previously undocumented, organ-specific toxicity linked to CD19-targeted CAR T-cell therapy in autoimmune disease. The syndrome, termed local immune effector cell-associated toxicity syndrome (LICATS), affected 77% of patients and resolved without lasting complications.